CFDA 2016 BE-GL [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2017-05-09 15:52 (2537 d 10:41 ago) – Posting: # 17334
Views: 9,704

Hi Shuanghe,

❝ […] in 2016, they also published another BE guideline (3rd attachment, in Chinese), which is basically a copy from FDA's BE guidance.


THX for the update!

❝ So it's a bit of mess now as you can imagine. e.g., FDA and EMA has quite different opinion about fasting and/or fed study for solid oral immediate-release dosage forms (depending on SPC's recommended administration method), in addition to many other aspects.


If I trust in Google-translate:
AUC0–72 only for drugs with a long half-life. What does the last sentence mean?
Seemingly no reference-scaling.
Multiple strengths of drugs with nonlinear PK (grater than proportional increase in AUC)?

EMA: highest strength.
FDA: highest therapeutic dose.
CFDA?


❝ Which guideline should one follow?


The latest one (as you did)… :-D

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,988 posts in 4,825 threads, 1,655 registered users;
97 visitors (0 registered, 97 guests [including 5 identified bots]).
Forum time: 02:33 CEST (Europe/Vienna)

The whole purpose of education is
to turn mirrors into windows.    Sydney J. Harris

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5